Scottish HTA Body OKs Vyxeos & Prevymis, But Rejects Kymriah In Lymphoma

 
• By Ian Schofield

The Scottish Medicines Consortium has OKd the use of two orphan drugs, Vyxeos for AML and Prevymis for preventing CMV reactivation, but rejected Novartis’s CAR-T therapy Kymriah, for use in lymphoma. 

Benefit_Cost
The SMC has weighed the evidence for three rare disease therapies • Source: Shutterstock

More from Health Technology Assessment

More from Market Access